Strong launch of Sandoz's epoetins in Germany
This article was originally published in Scrip
Novartis’s generics division,Sandoz, has reported biopharmaceutical sales of $97 million (+23% in local currencies) in the first half, which included the "strong launch" of its epoetin products in Germany (epoetin alfa Hexal, Binocrit and Abseamed (Medice)).
You may also be interested in...
Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.
A PFS benefit and favorable tolerability profile associated with AstraZeneca’s BTK inhibitor acalabrutinib used first-line in CLL, when given alone or combined with obinutuzumab, may serve it well against entrenched competitors and BTK inhibitors in clinical development.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.